Company intelligence / Profile preview

Metagone Biotech Inc.

Taipei, Taipei City/Taipei City Districts, Taiwanmetagone.com.tw ↗

Ownership: Private
Employees: ~20
Development stage: Phase 2

Overview

Metagone has completed Phase I trials for its first-generation oral anticancer agent MG-D1509. Its second-generation compound MG-D1609 has completed Phase I and is entering a Phase II basket trial across four solid tumor types. The company also has a small molecule drug for IPF in Phase IIa trials that shows superior anti-inflammatory effects compared to azithromycin in vitro. Additional assets target COPD, glaucoma, AMD, with most advanced programs at the Phase II stage.

Therapeutic areas: OphthalmologyOncologyPulmonology
Modalities: Small moleculesAntibody-drug conjugate (ADC)
Industry: Biotech

Drug pipeline

12 assets

MG-O-1002

11 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Metagone Biotech Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Metagone Biotech Inc..

Explore the full profile